Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13872391 | 0.84 | DRD2 (0.41) | LMNAALDH1A1 | |
| SCHEMBL3782873 | 0.81 | ALDH1A1 (0.43) | CA12CA9LMNAALDH1A1MEN1 | |
| SCHEMBL3775347 | 0.78 | ALDH1A1 (0.46) | CA12CA9LMNAALDH1A1MEN1 | |
| SCHEMBL4773233 | 0.76 | KMT2A (0.38) | CA12CA9LMNAALDH1A1MEN1 | |
| SCHEMBL16418145 | 0.75 | CASP3 (0.42) | CA12CA9ALDH1A1KMT2APOLB | |
| SCHEMBL3777727 | 0.74 | ACHE (0.44) | CA12CA9LMNAALDH1A1KDM4E | |
| SCHEMBL13872386 | 0.72 | ALDH1A1 (0.38) | LMNAALDH1A1MEN1KMT2APOLB | |
| SCHEMBL15457913 | 0.72 | ALDH1A1 (0.36) | LMNAALDH1A1MEN1KMT2APOLB | |
| SCHEMBL17983228 | 0.72 | ALDH1A1 (0.52) | CA12CA9LMNAALDH1A1ACHE | |
| SCHEMBL3780544 | 0.72 | LMNA (0.41) | LMNAALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CA12 2237/4885CA9 2405/4885LMNA 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.